Last updated: March 9, 2026
What is NDC 64896-0076?
NDC 64896-0076 corresponds to Xeljanz (tofacitinib) tablets, an immunosuppressant used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions. Manufactured by Pfizer, it is available in multiple dosing options.
Current Market Landscape
Market Size and Usage
- Global rheumatoid arthritis (RA) market: Estimated at US$ 22.4 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.5% until 2030 (Grand View Research, 2023).
- Xeljanz’s share: Approximately 12% of RA biologic and targeted synthetic DMARDs market in the U.S., with sales reaching US$ 1.6 billion in 2022.
- Treatment penetration: An increasing number of eligible patients are switching from biologics to oral small molecules like tofacitinib, driven by convenience and cost.
Competition
- Main competitors include AbbVie’s Humira, Eli Lilly’s Olumiant, Biogen’s Tysabri, and Roche’s Actemra.
- Biosimilars and generics are not yet available for tofacitinib in the U.S., but patents are expiring globally, opening potential for biosimilar entry.
Regulatory Status
- FDA approval: Approved for RA, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
- Patent expiration: Patents for tofacitinib are set to expire in 2025 in the U.S., with international patents expiring through 2027, which impacts generic/biosimilar market entry.
Pricing Analysis
Current Pricing
- Average wholesale price (AWP) for a 5 mg tablet: around US$ 75 per tablet.
- Monthly costs for an average adult dose (~10 mg twice daily): approximately US$ 1,500–1,800.
- Rebates and discounts: Estimated at 5–15%, leading to net prices lower than AWP.
Price Trends
- Prices have remained stable since FDA approval (2012), with minor reductions for bundled discounts.
- In markets with patent expiry considerations, biosimilar competition could reduce price by 20–40% within 2–3 years of biosimilar launch.
Price Projections (Next 3–5 Years)
| Year |
Estimated Price Range (per month) |
Key Factors |
| 2023 |
US$ 1,400 – 1,700 |
Stable, no biosimilar competition, limited rebates |
| 2024 |
US$ 1,200 – 1,500 |
Patent expiry in key markets, biosimilar approvals pending |
| 2025 |
US$ 1,000 – 1,300 |
Biosimilar market entry begins in Europe and Asia |
| 2026 |
US$ 900 – 1,200 |
Increased biosimilar adoption, price erosion continues |
| 2027 |
US$ 800 – 1,000 |
Full biosimilar market penetration, aggressive pricing policies |
Market Entry and Biosimilar Impact
- Biosimilars expected to enter in Europe by 2024 and North America by 2026.
- Price reductions of 25–40% in biosimilar markets are typical post-launch.
- Market share shifts depend on biosimilar pricing strategies and regional regulatory barriers.
Key Drivers and Risks
Drivers
- Growing autoimmune disease prevalence.
- Acceptance of oral targeted therapies.
- Patent expirations enabling biosimilar competition.
Risks
- Slower biosimilar adoption due to physician and insurer hesitance.
- Regulatory delays or restrictions.
- Patent litigations extending exclusivity.
Conclusions
The US market for tofacitinib (NDC 64896-0076) is mature, with stable prices currently. Upcoming patent expiration and biosimilar entry forecast a downward price trend averaging 15–25% over the next five years. Growth will be constrained by biosimilar competition but supported by increasing autoimmune disease prevalence.
Key Takeaways
- The current average monthly price of tofacitinib in the U.S. is approximately US$ 1,500, with stable pricing within the brand.
- Patent expiry begins in 2025, prompting biosimilar entries that could reduce prices by up to 40%.
- Market share growth depends on biosimilar launch success and clinician acceptance.
- Global markets may see earlier biosimilar access, influencing U.S. pricing strategies.
- Strategies for stakeholders include preparing for biosimilar competition and expanding indications.
FAQs
Q1: When will biosimilars for tofacitinib likely enter the U.S. market?
A1: Biosimilars are expected to enter in 2026, following patent expirations and regulatory approvals.
Q2: What factors influence the pricing of tofacitinib?
A2: Patent status, biosimilar competition, rebate strategies, and regional formulary decisions impact pricing.
Q3: Will biosimilars fully replace the branded tofacitinib?
A3: Not immediately; uptake depends on pricing, physician prescribing habits, and insurance coverage.
Q4: How are generic versions different from biosimilars in this context?
A4: Biosimilars are highly similar biologic copies of the original molecule, whereas generics are chemically identical small molecules.
Q5: What is the outlook for global tofacitinib markets?
A5: Markets outside the U.S. will experience biosimilar entry sooner, with prices declining faster, which could influence U.S. strategies.
References
- Grand View Research. (2023). Rheumatoid Arthritis Market Size, Share & Trends Analysis.
- FDA. (2012). Drug Approval: Xeljanz (tofacitinib).
- IQVIA. (2022). The Impact of Patent Expiry on Pharmaceutical Market Dynamics.
- Scrip Regulatory Affairs. (2023). Biosimilar Approvals and Market Trends.
- IMS Health. (2022). Pharmaceutical Pricing and Reimbursement Report.
